Table 1. Association of metabolite clusters with coronary artery disease (CAD).
Targeted metabolomics analysis was performed on blood samples from patients with and without CAD, involving an index (initial) cohort of 174 cases and 174 controls, and a replication cohort of 140 cases and 140 controls (adapted from reference 8).
Factor | Name | Individual Components | Initial Cohort P-value |
Replication Cohort P-value |
||
---|---|---|---|---|---|---|
Unadj | Adj* | Unadj | Adj* | |||
| ||||||
1 | Medium Chain Acylcarnitines |
C8, C10:1, C12, C10, C12:1, C10-OH:C8DC, C6-DC, C8:1- DC, C14:1, C14:2, C8:1-OH/C6:1-DC, C2 acylcarnitines |
0.001 | 0.01 | 0.15 | 0.03 |
2 | Long Chain Acylcarnitines |
C18:1, C18:2, C18, C16, C16:1, C20:4, C14:1, C14:2, C16:2, C14:1-OH |
0.28 | 0.34 | 0.03 | 0.01 |
3 | Long Chain Dicarboxyl/ Hydroxyl Acylcarnitines |
C18-OH/C16-DC, C20-OH/C18-DC, C20:1-OH/C18:1-DC, C16-OH/C14-DC, C18:1-OH/C16:1-DC, C14-OH/C12-DC, C12-OH:C10-DC, C14:1-OH, C20 |
0.10 | 0.36 | <0.0001 | 0.004 |
4 | BCAA Related | Phe, Tyr, leu/Ile, Met, Val, C5, Ala | 0.002 | 0.02 | 0.01 | 0.03 |
5 | Ketone Related | Ket, Hbut, Ala (−), C2, C4:OH, C14:1 | 0.18 | 0.33 | 0.54 | 0.41 |
6 | Various | C8:1, C10:3 | 0.56 | 0.75 | 0.79 | 0.92 |
7 | Amino Acids | Ser, Gly, FFA (−) | 0.19 | 0.13 | 0.04 | 0.18 |
8 | Dicarboxyls | C5-DC, C8:1-OH/C6:1-DC, Cit, C8:1-DC, C6-DC | 0.73 | 0.34 | 0.05 | 0.57 |
9 |
Urea Cycle
Related |
Arg, His, Cit, Ci4-DC:C4DC (−) | 0.0004 | 0.004 | 0.01 | 0.01 |
10 | Short Chain Acylcarnitines |
C3, C4:Ci4, C5 | 0.02 | 0.19 | 0.72 | 0.92 |
11 | Various | C5:1, C18:2-OH (−), C22 (−) | 0.62 | 0.13 | 0.03 | 0.01 |
12 | Various | Asx, C22 | 0.12 | 0.83 | <.0001 | <.0001 |
adjusted for diabetes, hypertension, smoking, dyslipidemia, family history, BMI; replication group additionally adjusted for age, race and sex.